Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin

Area of Science:

• Cardiovascular Research
• Mitochondrial Biology
• Pharmacology

Background:

• Mitochondrial calcium dysregulation is implicated in doxorubicin-induced cardiotoxicity.
• Previous studies showed doxorubicin disrupts cardiac mitochondrial calcium homeostasis.

Purpose of the Study:

• Characterize dose-dependent and cumulative effects of doxorubicin on mitochondrial calcium regulation.
• Assess the reversibility of doxorubicin-induced mitochondrial dysfunction.
• Investigate potential protective agents.

Main Methods:

• Sprague Dawley rats received weekly doxorubicin injections for 4-8 weeks.
• Cardiac mitochondria were isolated to assess calcium loading capacity with succinate.
• Mitochondrial content (ADP/ATP translocase) and coupling efficiency were analyzed.
• Effect of tamoxifen, DTT, monobromobimane, and cyclosporin A was evaluated.

Main Results:

• Doxorubicin treatment progressively reduced mitochondrial calcium loading capacity in a dose-dependent manner.
• This impairment persisted for 5 weeks post-treatment and was associated with irreversible histopathological changes.
• Cyclosporin A incubation reversed the diminished calcium loading capacity.
• Doxorubicin treatment reduced ADP/ATP translocase content but did not affect mitochondrial coupling efficiency.

Conclusions:

• Doxorubicin causes dose-dependent, irreversible mitochondrial calcium loading impairment.
• Reduced ADP/ATP translocase may alter mitochondrial permeability transition pore regulation, contributing to cardiotoxicity.
• Cyclosporin A shows potential in mitigating doxorubicin-induced mitochondrial dysfunction.